MedTrace Logo

Stem Cell Ophthalmology Treatment Study II

NCT03011541 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2025-03-20

No results posted yet for this study

Summary

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Conditions

  • Retinal Disease
  • Age-Related Macular Degeneration
  • Retinitis Pigmentosa
  • Stargardt Disease
  • Optic Neuropathy
  • Nonarteritic Ischemic Optic Neuropathy
  • Optic Atrophy
  • Optic Nerve Disease
  • Glaucoma
  • Leber Hereditary Optic Neuropathy
  • Blindness
  • Vision Loss Night
  • Vision Loss Partial
  • Vision, Low
  • Retinopathy
  • Maculopathy
  • Macular Degeneration
  • Retina Atrophy

Interventions

PROCEDURE

Arm 1

Procedure/ Surgery: RB (Retrobulbar) Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC) Procedure/Surgery: ST (Subtenon) Subtenon injection of Bone Marrow Derived Stem Cells (BMSC) Procedure/Surgery: IV (Intravenous) Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)

Sponsors & Collaborators

  • MD Stem Cells

    lead INDUSTRY

Principal Investigators

  • Steven Levy, MD · MD Stem Cells

  • Jeffrey Weiss, MD · Coral Springs Florida, Vienna Austria, Dubai UAE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2026-07-31
Completion
2027-07-31

Countries

  • United States
  • Austria
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03011541 on ClinicalTrials.gov